Envestnet Portfolio Solutions Inc. Has $29.11 Million Stock Holdings in AbbVie Inc. $ABBV

Envestnet Portfolio Solutions Inc. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,738 shares of the company’s stock after selling 3,733 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in AbbVie were worth $29,113,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Evolution Wealth Management Inc. bought a new stake in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth about $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter worth about $39,000. Finally, Bear Mountain Capital Inc. increased its position in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Bank of America lifted their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Scotiabank began coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $218.05 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm’s 50 day simple moving average is $225.87 and its 200 day simple moving average is $216.99. The company has a market capitalization of $385.38 billion, a price-to-earnings ratio of 165.19, a P/E/G ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.